Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Overview

The purpose of this study is to determine if ticagrelor is as effective as clopidogrel in rate of onset and degree of platelet inhibition for patients with non-ST elevation of acute coronary syndrome (NSTE-ACS) undergoing ad hoc percutaneous coronary intervention (PCI) with bivalirudin.

Full Title of Study: “A Phase IV, Randomised, Multi-Centre, Open Label Study, Comparing Ticagrelor Versus Clopidogrel in Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Patients Undergoing Percutaneous Coronary Intervention (PCI) With Bivalirudin”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2015

Detailed Description

Multi-center, open-label study that will compare the onset of the platelet inhibition with ticagrelor versus clopidogrel when administered with bivalirudin during PCI on a background therapy of aspirin in patients with NSTE-ACS.

Interventions

  • Drug: ticagrelor
    • Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
  • Drug: clopidogrel
    • Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.

Arms, Groups and Cohorts

  • Experimental: Ticagrelor
    • 90 mg oral tablet
  • Active Comparator: Clopidogrel
    • 300 mg oral tablet

Clinical Trial Outcome Measures

Primary Measures

  • P2Y12 Reaction Units (PRU) Using VerifyNow™ at 0.5 Hours After Loading Dose
    • Time Frame: 0.5 hours post loading dose
    • PRU at 0.5 hours after a single oral loading dose of either ticagrelor 180 mg or clopidogrel 600 mg given at the time of the bivalirudin bolus
  • P2Y12 Reaction Units (PRU) Using VerifyNow™ at 1 Hour After Loading Dose
    • Time Frame: 1 hour post loading dose
    • PRU at 1 hour after a single oral loading dose of either ticagrelor 180 mg or clopidogrel 600 mg given at the time of the bivalirudin bolus

Participating in This Clinical Trial

Inclusion Criteria

  • Hospitalised for chest pain and potential acute coronary syndrome. – Onset of the most recent cardiac ischemic symptoms must occur within 7 days before randomisation and documented by cardiac ischemic symptoms of ≥ 10 min duration at rest and at least 2 of the following: ST segment changes on electrocardiogram (ECG) indicative of ischemia, or Positive biomarker evdience of myocardial necrosis, or other risk factors such as: 60 yrs of age or older, previous myocardial infarction or coronary bypass surgery, multi-vessel coronary artery disease, diabetes mellitus, peripheral arterial disease, chronic renal disfunction. – Females must be either surgically sterile or post-menopausal. – Activated Clotting Time (ACT) </= 300 at the time of study treatment Exclusion Criteria:

  • Participation in another clinical study with an investigational product during the last 30 days. – Current acute complication of percutaneous coronary intervention or coronary bypass surgery. – Any contraindication to ticagrelor, clopidogrel or bivalirudin. – ST elevation myocardial infraction within 24 hours of study entry. – Any indications for oral anticoagulation or aspirin dose other than 75 to 100 milligrams (mg) daily. – Planned use of omeprazole or esomeprazole. – Patients with known bleeding or coagulation disorders; patients requiring dialysis; patients who have an inability to swallow medication. – Patients with known bleeding diathesis or coagulation disorder; history of intracranial bleed. – Use of Intravenous (IV) heparin less than 2 hours before procedure. – Sustained uncontrolled high blood pressure

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 130 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AstraZeneca
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marc Cohen, MD, Principal Investigator, Newark Beth Israel Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.